好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Addition of Azathioprine and Corticosteroids to the Interferon Therapy Reduces Long-Term Clinical Progression in Multiple Sclerosis Patients with High T2-Lesion Volume
MS and Related Diseases
(-)
053
Authors/Disclosures
No disclosure on file
Edouard Kamel, MD Dr. Kamel has nothing to disclose.
Dana Horakova Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dana Horakova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.
Ondrej Dolezal, MD (Biogen Idec (Czech Republic) s.r.o.) No disclosure on file
Jan Krasensky, MD No disclosure on file
Manuela Vaneckova Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Manuela Vaneckova has received research support from Czech Ministry of Health project—grants NU 22-04-00193 . Manuela Vaneckova has received research support from Czech Ministry of Health project - RVO VFN 64165 . Manuela Vaneckova has received personal compensation in the range of $500-$4,999 for serving as a principal investigator with Czech Ministry of Health project—grants NU 22-04-00193 .
No disclosure on file
Eva Havrdova, MD (Neurologicka Klinika 1 LF UK) Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Havrdova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi.